Shilpa Medicare is currently trading at Rs. 291.30, up by 23.20 points or 8.65% from its previous closing of Rs. 268.10 on the BSE.
The scrip opened at Rs. 267.95 and has touched a high and low of Rs. 298.75 and Rs. 263.95 respectively. So far 332009 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 605.00 on 04-Jan-2022 and a 52 week low of Rs. 265.85 on 22-Dec-2022.
Last one week high and low of the scrip stood at Rs. 299.00 and Rs. 263.95 respectively. The current market cap of the company is Rs. 2499.89 crore.
The promoters holding in the company stood at 50.01%, while Institutions and Non-Institutions held 16.22% and 33.77% respectively.
Shilpa Medicare has introduced Capecitabine 1000 MG dispersible tablet for the first time in the world, with novel technology of faster dispersion within 90 seconds. The company has launched the product in the Indian market on December 16, 2022 and is further looking to introduce Capebel 1 gm DT in various international markets through its partners and clients.
Till now Capecitabine is available in 500 mg and 150 mg tablets and the recommended doses are 3500 to 4000 mg /day divided into two doses for 14 consecutive days requiring 7 to 8 tablets to be consumed by the patients daily. This was an unmet need and remains a big issue for Cancer patients. Swallowing of 7 to 8 tablets pose a challenge in completing daily doses since most cancer patients have swallowing difficulties and hence a significant patient compliance issue.
With the revolutionary introduction of the company’s new brand, ‘Capebel’, patients will be required to just drop the tablets in 100 mL water and allow the tablets to dissolve and then drink dissolved solution. Hence from 7 to 8 tablets a day, patients just need to drink 100 mL water twice daily with dissolved tablets in it.
Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1777.65 |
| Dr. Reddys Lab | 1194.55 |
| Cipla | 1465.65 |
| Lupin | 2043.30 |
| Zydus Lifesciences | 944.25 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Claim your FREE 15-day access to the most practical investing handbook.
Hurry, limited to the first 10 users today!
FREE Become a savvy and confident
stock investor.
Hurry, limited to the first 10 users today!
Download APP
